Testosterone and andropause: The feasibility of testosterone replacement therapy in elderly men

Pharmacotherapy

Volumn 19, Issue 8, 1999, Pages 951-956

  Lund, Brian C ^a   Bever Stille, Kristine A ^a   Perry, Paul J ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGING; CANCER RISK; DRUG SAFETY; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; MALE; MUSCLE WEAKNESS; PSYCHOLOGICAL ASPECT; REVIEW; RISK BENEFIT ANALYSIS; TESTOSTERONE BLOOD LEVEL;

AGED; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 0032771269     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.11.951.31574     Document Type: Review

References (37)

1. Carr BR, Bradshaw KD. Disorders of the ovary and female reproductive tract. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, eds. Harrison's principles of internal medicine. New York: McGraw-Hill, 1998:2102.
2. Stembach H. Age-associated testosterone decline in men: clinical issues for psychiatry. Am J Psychiatry 1998;155:1310-18.
3. Urban RJ. Neuroendocrinology of aging in the male and female. Endocrinol Metab Clin North Am 1992;21:921-31.
4. Wheeler MJ. The determination of bio-available testosterone. Ann Clin Biochem 1995;32:345-57.
5. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts male aging study. J Clin Endocrinol Metab 1991;73:1016-25.
6. Vermeulen A, Kaufman JM. Ageing of the hypothalamopituitary-testicular axis in men. Horm Res 1995;43:25-8.
7. McKinlay JB, Longcope C, Gray A. The questionable physiologic and epidemiologic basis for a male climacteric syndrome: preliminary results from the Massachusetts male aging study. Maturitas 1989;11:103-15.
8. Deslypere JP, Vermeulen A. Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metab 1984;59:955-62.
9. Barrett-Connor E, Khaw K. Cigarette smoking and increased endogenous estrogen levels in men. Am J Epidemiol 1987;126:187-92.
10. Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. J Clin Endocrinol Metab 1977;45:1211-19.
11. Persky H, O'Brien CP, Fine E, Howard WJ, Khan MA, Beck RW. The effect of alcohol and smoking on testosterone function and aggression in chronic alcoholics. Am J Psychiatry 1977:134:621-5.
12. Morley JE, Perry HM, Kaiser FE, et al. Effects of testosterone replacement therapy in old hypogonadal men: a preliminary study. J Am Geriatr Soc 1993;41:149-52.
13. Sih R, Morley JE, Kaiser FE, Perry HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12 month randomized controlled trial. J Clin Endocrinol Metab 1997;82:1661-7.
14. Urban RJ, Bodenburg YH, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995;269:E820-6.
15. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992;75:1092-8.
16. Wang C, Swerdloff RS. Androgen replacement therapy. Ann Med 1997;29:365-70.
17. Jackson J A, Riggs MW, Spiekerman AM. Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci 1992;304:4-8.
18. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal men: a retrospective analysis. J Clin Endocrinol Metab 1997;82:3793-6.
19. Zgliczynski S, Ossowski M, Slowinska-Srzednicka J, et al. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 1996;121:35-43.
20. Uyanik BS, Ari Z, Gumus B, Yigitoglu MR, Arslan T. Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. Jpn Heart J 1997;38:73-82.
21. Schiavi RC, Rehman J. Sexuality and aging. Urol Clin North Am 1995;22:711-26.
22. O'Carroll R, Shapiro C, Bancroft J. Androgens, behaviour and nocturnal erection in hypogonadal men: the effects of varying the replacement dose. Clin Endocrinol 1985;23:527-38.
23. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998;279:688-95.
24. Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci 1994;108:325-32.
25. VanGoozen SHM, Cohen-Kettenis PT, Gooren LJG, Frijda NH, Van de Poll NE. Activating effects of androgens on cognitive performance: causal evidence in a group of female-to-male transsexuals. Neuropsychologia 1994;32:1153-7.
26. Christiansen K, Knussmann R. Sex hormones and cognitive function in men. Neuropsychobiology 1987;18:27-36.
27. Seidman SN, Rabkin JG. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J Affect Disord 1998;48:157-61.
28. Palsson S, Skoog I. The epidemiology of affective disorders in the elderly: a review. Int Clin Psychopharmacol 1997;12(suppl 7):S3-13.
29. Meehan PJ, Saltzman LE, Sattin RW. Suicides among older United States residents: epidemiologic characteristics and trends. Am J Public Health 1991;81:1198-2000.
30. Pearson JL, Conwell Y. Suicide in late life: challenges and opportunities for research. Int Psychogeriatr 1995;7:131-5.
31. Grabbe L, Demi A, Camann MA, Potter L. The health status of elderly persons in the last year of life: a comparison of deaths by suicide, injury, and natural causes. Am J Public Health 1997;87:434-7.
32. Vermeulen A. The male climacterium. Ann Med 1993;25:531-4.
33. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-26.
34. Nomura AMY, Stemmermann GN, Chyou P, Hendetson BE, Stanczyk RZ. Serum androgens and prostate cancer. Cancer Epidemiol Biomarkers Prev 1996;5:621-5.
35. Jackson JA, Waxman J, Spiekerman AM. Prostatic complications of testosterone replacement therapy. Arch Intern Med 1989;149:2365-6.
36. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
37. Morgentaler A, Bruning CO, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996;276:1904-6.